Pfizer Reaffirms Full-Year Guidance

Pfizer reaffirmed its full-year guidance, but lowered its 2012 revenue guidance to reflect the impact of recently enacted U.S. health care legislation.
Author:
Publish date:


NEW YORK (TheStreet) -- Pfizer (PFE) - Get Report reaffirmed its full-year guidance after beating first-quarter targets, but lowered its 2012 revenue guidance to reflect the impact of recently enacted U.S. health care legislation.

Pfizer said it expects full-year adjusted earnings of $2.10 to $2.20 a share, compared with the average analyst estimate of $2.18, and revenue of $67 billion to $69 billion. The company is reducing its targeted revenue range for 2012 by $800 million to between $65.2 billion and $67.7 billion to reflect the anticipated financial impact of the health care changes.

For 2012, Pfizer is expecting adjusted earnings of between $2.25 and $2.35 a share.

During the first quarter, the company reported net income fell 26% to $2.026 billion, or 25 cents a share. Adjusted earnings were 60 cents a share.

Revenue rose 54% to $16.8 billion, favorably impacted by the addition of the legacy

Wyeth

products and foreign exchange, but unfavorably impacted by legacy Pfizer products. They also reflect a reduction of $56 million due to the recently enacted U.S. health care legislation.

The consensus earnings estimate for the quarter was 53 cents a share on revenue of $16.58 billion.

-- Reported by Andrea Tse in New York

Follow TheStreet.com on

Twitter

and become a fan on

Facebook.

Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.